This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Taniguchi, K. Articles by Kuwano, M. Search for Related Content PubMed PubMed Citation Articles by Taniguchi, K. Articles by Kuwano, M.

Drug-induced Down-Regulation of Topoisomerase I in Human Epidermoid Cancer Cells Resistant to Saintopin and Camptothecins¹

Department of Biochemistry, Kyushu University School of Medicine, Maidashi, Higashi-ku, Fukuoka 812-82 [K. T., K. Ko., K. Ka., M. W., M. K.], and Second Department of Surgery, Nagasaki University School of Medicine, Sakamoto, Nagasaki 852 [T. K.], Japan

The anticancer agent saintopin induces DNA cleavage mediated by both topoisomerase (topo) I and topo II in vitro through stabilization of the reversible enzyme-DNA cleavable complex. We established saintopinresistant cell lines (KB/STP-1 and KB/STP-2) from human epidermoid cancer KB cells by stepwise exposure to increasing doses of the drug. KB/STP-1 and KB/STP-2 cells showed 12- and 44-fold increases, respectively, in resistance to saintopin relative to that of KB cells. Both saintopin-resistant cell lines showed only small reductions in sensitivity to the topo II inhibitor etoposide but developed marked cross-resistance to the topo I-targeting camptothecin derivative CPT-11 [(4s)-4,11-diethyl-4-hydroxy-9-[(4-piperidinopiperidino)carbonyloxy] dione hydrochloride trihydrate] and its active form, SN-38 (7-ethyl-10-hydroxycamptothecin). In contrast, both KB/STP-1 and KB/STP-2 cells showed increased collateral sensitivity to cisplatin, a nitrosourea derivative, mitomycin C, and UV light. The protein concentration, activity, and mRNA abundance of both topo I and topo II were similar in KB/STP-1, KB/STP-2, and the parental KB cells. There were no significant changes in the drug-stabilized topo-DNA cleavable complex formation in KB and KB/STP-2 cells. Two point mutations were detected in topo I cDNA from KB/STP-2 cells, but these were also present in KB cells. Topo I mRNA abundance decreased markedly immediately after exposure of KB/STP-2 cells to saintopin; no such effects were apparent in KB cells. In contrast, topo II mRNA was not markedly affected by saintopin in either KB or KB/STP-2 cells. Treatment with CPT-11 or SN-38 also induced a markedly greater and more persistent reduction in topo I mRNA abundance in KB/STP-2 cells than in KB cells. Etoposide had no marked effect on topo I mRNA abundance in either KB/STP-2 or KB cells. Topo I mRNA was highly unstable in KB/STP-2 cells in comparison to KB cells when incubated with saintopin. This novel regulation of topo I mRNA by topo I-targeting agents could be associated with acquirement of drug resistance to saintopin or SN-38/CPT-11 in KB/STP-2 cells.

¹ This work was supported in part by a Grant-in-Aid for cancer research from the Ministry of Education, Science, and Culture of Japan, by the Yasuda Memorial Medical Grant for Cancer Research, and by the Fukuoka Anticancer Research Fund.

² To whom requests for reprints should be addressed.

Received 12/12/95. Accepted 3/19/96.

This article has been cited by other articles:

				R van Gijn, R. Lendfers, J. Schellens, A Bult, and J. Beijnen Dual topoisomerase I/II inhibitors Journal of Oncology Pharmacy Practice, September 1, 2000; 6(3): 92 - 108. [Abstract] [PDF]

				N. Fujii, Y. Yamashita, T. Mizukami, and H. Nakano Correlation between the Formation of Cleavable Complex with Topoisomerase I and Growth-Inhibitory Activity for Saintopin-Type Antibiotics Mol. Pharmacol., February 1, 1997; 51(2): 269 - 276. [Abstract] [Full Text] [PDF]